Clinical trial
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And…
NCT00364429 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00364429 |
|---|---|
| Title | SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia |
| Official title | Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | [123]I-CNS 1261, Lorazepam, Risperidone |
| Enrollment | 55 |
| Start date | Jul 1, 2005 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Aug 15, 2006 |
| Last update posted | Jan 11, 2016 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: